Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)
Rheumatol. Int. 2024 Apr 30:1–7 DOI: 10.1007/s00296-024-05589-2 https://pubmed.ncbi.nlm.nih.gov/38687385/
This study by Jaïs, et al. demonstrated the corticosteroid-sparing effect of belimumab among SLE patients who often experience visceral damage due to corticosteroids rather than disease activity itself.